SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2021-11-05
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of SD-101 when given together with nivolumab and
radiation therapy in treating patients with pancreatic cancer that does not respond to
treatment with chemotherapy (chemotherapy refractory) and has spread to other places in the
body (metastatic). Drugs used in chemotherapy, such as SD-101, work in different ways to stop
the growth of cancer cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells
and shrink tumors. Giving SD-101, nivolumab, and radiation therapy may work better in
treating patients with pancreatic cancer compared to nivolumab or radiation therapy alone.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Bristol-Myers Squibb Dynavax Technologies Corporation National Cancer Institute (NCI)